Format

Send to

Choose Destination
See comment in PubMed Commons below
Nanomedicine. 2014 Apr;10(3):661-8. doi: 10.1016/j.nano.2013.10.008. Epub 2013 Nov 4.

Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance.

Author information

1
Center for Systems Biology, Massachusetts General Hospital, Boston, MA.
2
Center for Systems Biology, Massachusetts General Hospital, Boston, MA; Department of Imaging, Massachusetts General Hospital, Fruit St, Boston, MA.
3
Department of Imaging, Massachusetts General Hospital, Fruit St, Boston, MA.
4
Center for Systems Biology, Massachusetts General Hospital, Boston, MA; Massachusetts General Hospital Cancer Center, Boston, MA.
5
Department of Pathology, Massachusetts General Hospital, Fruit St, Boston, MA.
6
Department of Imaging, Massachusetts General Hospital, Fruit St, Boston, MA. Electronic address: JSHEPARD@PARTNERS.ORG.
7
Center for Systems Biology, Massachusetts General Hospital, Boston, MA; Department of Imaging, Massachusetts General Hospital, Fruit St, Boston, MA; Department of Systems Biology, Harvard Medical School, Boston, MA; Massachusetts General Hospital Cancer Center, Boston, MA. Electronic address: rweissleder@mgh.harvard.edu.

Abstract

Advances in nanotechnology and microfluidics are enabling the analysis of small amounts of human cells. We tested whether recently developed micro-nuclear magnetic resonance (μNMR) technology could be leveraged for diagnosing pulmonary malignancy using fine needle aspirate (FNA) of primary lesions and/or peripheral blood samples. We enrolled a cohort of 35 patients referred for CT biopsy of primary pulmonary nodules, liver or adrenal masses and concurrently obtained FNA and peripheral blood samples. FNA sampling yielded sufficient material for μNMR analysis in 91% of cases and had a sensitivity and specificity of 91.6% and 100% respectively. Interestingly, among blood samples with positive circulating tumor cells (CTC), μNMR analysis of each patient's peripheral blood led to similar diagnosis (malignant vs benign) and differential diagnosis (lung malignancy subtype) in 100% and 90% (18/20) of samples, respectively. μNMR appears to be a valuable, non-invasive adjunct in the diagnosis of lung cancer.

FROM THE CLINICAL EDITOR:

The authors of this study established that recently developed micro-nuclear magnetic resonance (μNMR) technology can be leveraged for diagnosing pulmonary malignancy using fine needle aspirate (FNA) of primary lesions and/or peripheral blood samples derived from 35 patients, suggesting practical clinical applicability of this technique.

KEYWORDS:

Bioorthogonal click chemistry; Circulating tumor cell; Iron-oxide nanoparticles; Point of care diagnosis; μNMR

PMID:
24200523
PMCID:
PMC3966960
DOI:
10.1016/j.nano.2013.10.008
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center